AXD2 Stock Overview
A commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Heron Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.18 |
| 52 Week High | US$3.46 |
| 52 Week Low | US$1.00 |
| Beta | 1.55 |
| 1 Month Change | 34.90% |
| 3 Month Change | 44.75% |
| 1 Year Change | -22.14% |
| 3 Year Change | -56.93% |
| 5 Year Change | -78.63% |
| Change since IPO | -75.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXD2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.1% | 0.4% | -0.5% |
| 1Y | -22.1% | -12.7% | 13.3% |
Return vs Industry: AXD2 underperformed the German Biotechs industry which returned -13% over the past year.
Return vs Market: AXD2 underperformed the German Market which returned 13.3% over the past year.
Price Volatility
| AXD2 volatility | |
|---|---|
| AXD2 Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: AXD2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AXD2's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 122 | Craig Collard | www.herontx.com |
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Heron Therapeutics, Inc. Fundamentals Summary
| AXD2 fundamental statistics | |
|---|---|
| Market cap | €335.10m |
| Earnings (TTM) | -€12.55m |
| Revenue (TTM) | €133.36m |
2.5x
P/S Ratio-26.7x
P/E RatioIs AXD2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXD2 income statement (TTM) | |
|---|---|
| Revenue | US$144.29m |
| Cost of Revenue | US$55.33m |
| Gross Profit | US$88.95m |
| Other Expenses | US$102.53m |
| Earnings | -US$13.58m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.089 |
| Gross Margin | 61.65% |
| Net Profit Margin | -9.41% |
| Debt/Equity Ratio | -519.2% |
How did AXD2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 00:49 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Heron Therapeutics, Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Jonathan Aschoff | B. Riley Wealth |